companies initiating the future

Compressing hit-to-lead and lead optimization from months into weeks, in silico.

Making clinical and real-world data AI-ready in hours instead of months.

Making lung cancer screening as easy to reach as an ordinary blood draw.

Catching sepsis in the hours it can still be treated, by reading the immune response.

Manufacturing human cells and organoids reproducibly, at the scale therapy needs.

Getting more patients onto therapy, and keeping them there, direct to the patient.

Bringing rigorous clinical trials to the communities patients actually live in.

Staging liver fibrosis from a blood draw so MASH treatment can reach patients.